

Supplementary Table 4. Number of patients with event and incidence rates of study outcomes

Variable	TZD (<i>n</i> =56,794)		SGLT-2i (<i>n</i> =56,794)	
	No. of events	IR, /1,000 PY	No. of events	IR, /1,000 PY
Stroke	419	4.11	443	4.22
Ischemic stroke	342	3.35	368	3.50
Hemorrhagic stroke	64	0.62	72	0.68
MI	161	1.57	181	1.72
CV death	174	1.70	184	1.75
3-Point MACE	703	6.90	757	7.23
HF	135	1.32	87	0.83

TZD, thiazolidinedione; SGLT-2i, sodium-glucose cotransporter-2 inhibitor; IR, incidence rate; PY, person-years; MI, myocardial infarction; CV, cardiovascular; MACE, major adverse cardiovascular events; HF, heart failure.